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Tg(MMTV-PyMT)634Mul). In vivo binding specificity studies (n=26 tumors) showed that ultrasound imaging signal was significantly higher (P<0.001) using MB VEGFR2 compared to nontargeted microbubbles and imaging signal significantly decreased (P<0.001) by blocking antibodies. Ultrasound molecular imaging signal significantly increased (P<0.001), when breast tissue (n=315 glands) progressed from normal (1.65±0.17 a.u.) to hyperplasia (4.21±1. 16 ), DCIS (15.95±1.31) and invasive cancer (78.1±6.31) and highly correlated with ex vivo VEGFR2 expression (R 2 =0.84; 95% CI, 0.72, 0.91; P<0.001). At an imaging signal threshold of 4.6 a.u., ultrasound molecular imaging differentiated benign from malignant entities with a sensitivity of 84% (95% CI, 78, 88) and specificity of 89% (95% CI, 81, 94). In a prospective screening trail (n=63 glands) diagnostic performance of detecting DCIS and breast cancer was assessed and two independent readers correctly diagnosed malignant disease in >95% of cases and highly agreed between each other (ICC=0.98; 95% CI, 97, 99). These results suggest that VEGFR2targeted ultrasound molecular imaging allows highly accurate detection of DCIS and breast cancer in transgenic mice and may be a promising approach for early breast cancer detection in women.
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INTRODUCTION
Breast cancer is the most common cancer diagnosed in women in the USA, and the second leading cause of death from cancer in women (1) . The American Cancer Society estimates 229,060 new diagnoses of breast cancer and 39,920 deaths from this cancer in 2012 in the USA (1) . Earlier detection can substantially reduce deaths from breast cancer. Screening mammography, currently the most frequently performed imaging procedure for breast cancer screening, has been shown to decrease mortality by 22% in women 50 years or older, and by 15% in women 40 to 49 years (2) .
However, diagnostic accuracy of mammography in detecting breast cancer is reduced in women with dense breasts. More than 50% of women younger than 50 years have either heterogeneously dense or very dense breast tissue, as do at least one third of women older than 50 years (3) . In women with dense breast tissue, mammographic sensitivity regarding cancer detection can be as low as 30% to 48% (4, 5) with much higher interval cancer rates (5, 6) and worse prognosis in subsequent clinically detected cancers (7) . Therefore, recent studies have addressed the value of adding ultrasound imaging to screening mammography (4, (8) (9) (10) (11) (12) . A multicenter study of 2,637 women at increased risk for breast cancer with dense breast tissue showed that breast cancer was diagnosed on ultrasound alone in 12 of 40 patients (30%) (7) . However, the positive predictive value (PPV) of ultrasound for cancer detection in that study was only 8.6%, resulting in a large number of unnecessary callbacks and biopsies (7) . In addition, the sensitivity of ultrasound performed alone in detecting invasive breast cancer was only 50% (7) and even lower (27%) in another prospective multimodality screening study of 609 asymptomatic high risk women (13) . These findings underscore that further improvements in ultrasound are critically needed to increase its accuracy in diagnosing malignant precursor or invasive breast cancer lesions, should it be included as a complementary imaging modality into breast cancer screening protocols.
Ultrasound molecular imaging combines the advantages of ultrasound with the capabilities of molecular imaging to visualize molecular signatures with high sensitivity and specificity in vivo (14, 15) . Microbubble (MB) contrast agents already in clinical use with ultrasound can be further on July 20, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 17, 2013; DOI: 10.1158/0008-5472. chemically modified to accumulate at vascular endothelial cells over-expressing molecular markers associated with either precursor lesions or invasive cancer (14, 16, 17) . Vascular endothelial growth factor receptor type 2 (VEGFR2), a transmembrane receptor tyrosine kinase, is a well-studied molecular marker overexpressed on angiogenic vascular endothelial cells of cancer (18, 19) . Several studies have demonstrated increased angiogenesis and VEGFR2 overexpression in invasive breast cancer in human breast cancer tissues (19) (20) (21) . Recent immunohistochemistry studies suggest increased angiogenesis even at the precursor ductal carcinoma in situ (DCIS) stage (22) . Ultrasound molecular imaging of VEGFR2 expression on angiogenic vessels in DCIS and invasive breast cancer may therefore be a promising new approach for improving diagnostic accuracy of ultrasound in earlier detection of precursor lesions and breast cancer.
In our study, we evaluated how ultrasound molecular imaging can depict different histological stages of breast cancer development, including mammary hyperplasia, DCIS, and invasive breast cancer, in the well-established FVB/N-Tg(MMTV-PyMT)634Mul transgenic mouse model (23) (24) (25) by using a new, clinical-grade VEGFR2-targeted contrast MB. In a prospective screening trial of transgenic and control mice we show that DCIS and invasive breast cancer can be detected with high diagnostic accuracy and reliability by ultrasound molecular imaging. 
MATERIALS AND METHODS

Transgenic Mouse Model
All procedures involving the use of laboratory animals were approved by the Institutional Administrative Panel on Laboratory Animal Care at Stanford University. A transgenic mouse model of breast cancer (FVB/N-Tg(MMTV-PyMT)634Mul) was used for all experiments. In this model, the mammary epithelium transforms into different histological stages of breast cancer development, similar to disease progression in humans, including mammary hyperplasia, ductal carcinoma in situ (DCIS), and invasive carcinoma (24, 25) .
Design of Microbubbles
A novel clinical-grade VEGFR2-targeted microbubble contrast agent (MB VEGFR2 ) containing perfluorobutane and nitrogen (BR55; synthesized under GMP by Bracco Suisse SA, Geneva, Switzerland), was prepared as described previously (26) . Briefly, a heterodimeric peptide (5.5-kDa) that binds to VEGFR2 with high affinity (dissociation constant, K D = 0.5 nmol/L) was conjugated with the amino group of DSPE-PEG2000-NH 2 (1,2-distearoyl-sn-glycerol-3phosphoethanolamine-N-[amino (polyethylene glycol)-2000) to form VEGFR2-binding lipopeptides (27, 28) . This lipopeptide construct was purified and incorporated into the phospholipid-based shell of MB (mean number of heterodimeric peptides per square micrometer on the MB shell: 34200 ± 1300; range, 31800 -36600). The resultant product was lyophilized and stored in septum sealed vials. Before injection in mice, MB were reconstituted in 2 ml of 5% glucose. The mean diameter of MB VEGFR2 was 1.5 μm (range, 1-3 μm), as assessed by using a cell counter and sizer (Multisizer III Coulter Counter; Beckman Coulter, Fullerton, CA) (26).
MB VEGFR2 was previously shown to cross-react with murine, rat, and human VEGFR2 (26, 29) .
Non-targeted MB that lack the VEGFR2 specific lipopeptide construct were used as control MB (MB Control ).
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Imaging Protocol
Ultrasound molecular imaging was performed as described previously (30) and a detailed description of the imaging protocol is provided in the Supplementary Materials. Images representing signal from adherent MB (molecular imaging signal) were displayed as color maps overlaid on B-mode images, automatically generated by using commercially available Vevo CQ software (VisualSonics, Toronto, Canada). The scale for the color maps was kept constant for all images.
Binding Specificity of Microbubbles to VEGFR2 in Transgenic Mouse Model
In the first part of the imaging study, VEGFR2 binding specificity of MB VEGFR2 was tested in 26 transgenic mice bearing tumors ( Figure 1 ) in an intra-animal comparison study using MB VEGFR2 and MB Control , as well as by performing in vivo competition experiments (details are provided in Supplementary Materials). To minimize any bias from repetitive injections in the same mice, injections were separated by at least 30 minutes waiting time to allow clearance of MB from previous injections (31) .
Correlation Between In Vivo Imaging and Histology
Ultrasound Imaging
To determine how VEGFR2-targeted ultrasonic imaging signal varies in different histological stages of breast cancer progression (from normal mammary gland tissue to hyperplasia, DCIS and invasive breast cancer), in the second part of the study, the mammary glands of transgenic mice (n=233) and glands of age-matched control litter mates (n=82) were imaged using MB VEGFR2 as described above at different stages of breast cancer development between ages 4 and 10 weeks, and the in vivo imaging signals were correlated with ex vivo histological findings ( Figure   1 ). A total of 315 mammary glands were imaged and all mammary glands were excised immediately after imaging to allow direct correlation between in vivo imaging findings and ex vivo histology. Before isolating the mammary glands, the imaging plane (position of ultrasound on July 20, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Imaging Data Analysis
After each imaging session, the imaging data sets of all mice were analyzed offline in random order at a dedicated workstation with commercially available software (Visualsonics, Toronto, Ontario, Canada). Analysis was performed in a blinded fashion by one independent reader, blinded to the type of MB (MB VEGFR2 versus MB Control ), the age of the animals and the animal type (transgenic or control). Regions of interest (ROI) were drawn over the mammary gland and the magnitude of imaging signal from attached MB was assessed by calculating an average for preand post-destruction imaging signals and subtracting the average post-destruction signal from the average pre-destruction signal, as described previously ( Figure 1 ) (32, 33) .
Ex Vivo Analysis of Mammary Glands
Ex vivo analysis of mammary glands for quantitative immunofluorescence (QIF), and microvessel density (MVD) were performed using standard techniques (see Supplementary Materials).
Calculation of Ultrasonic Molecular Imaging Signal Thresholds
To determine thresholds of VEGFR2-targeted ultrasound imaging signals to allow discrimination of benign (normal and hyperplasia) from malignant histological entities (DCIS and invasive breast cancer) based on imaging, receiver operating characteristic (ROC) curves were constructed and the sensitivity and specificity for potential imaging signal threshold levels and corresponding 95% confidence intervals were calculated using the data sets from the above described imaging/histology correlation study from 315 mammary glands. Additionally, a non-parametric logistic regression model was used to predict the probability of a histological stage (normal, hyperplasia, DCIS or invasive breast cancer) based on ultrasound imaging. Based on these on July 20, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Prospective Imaging Trial in Screening Setting
In the third part of the study, the diagnostic accuracy of ultrasonic molecular imaging in differentiating the four different histological tissues was assessed in a prospective screening setting ( Figure 1 ). For this purpose, an additional 63 mammary glands from transgenic and wild type littermates at random ages between 4 and 10 weeks were scanned. This study design was chosen to simulate a screening scenario with "patients" with and without increased risk for breast cancer (transgenic and wild type littermates) that present with different mammary gland pathologies at the time of screening ultrasound. The imager was blinded to the age and group of mice (transgenic vs. normal) at the time of screening ultrasound. After each imaging exam, image analysis was performed as described above by two independent readers. Both readers were blinded to the age of the animals and the animal type (transgenic or control). Both readers were asked to render a diagnosis for each mammary gland (malignant versus benign) based on the ultrasonic molecular imaging signal obtained from the mammary gland and using the imaging signal threshold level of 4.6. a.u. as calculated above. The mammary glands were excised and ex vivo analysis of the mammary glands was performed as described above. The diagnosis at pathology was used as reference standard to calculate diagnostic accuracy of ultrasound molecular imaging in diagnosing malignant versus benign disease in the prospective screening setting. One of the two readers performed a repeat analysis eight weeks after the first imaging analysis to assess intra-operator agreement.
Statistical Analysis
All data are represented as mean ± standard deviations. 
RESULTS
Clinical-grade MB VEGFR2 bind to murine VEGFR2 in transgenic mice with high specificity.
As a first step, we tested binding specificity of clinical grade MB VEGFR2 to murine VEGR2 in 26 breast cancers with different sizes in transgenic mice (mean diameter, 7 mm; range, 3 -12 mm).
Following intravenous administration of MB VEGFR2 , in vivo ultrasound imaging signal obtained from breast cancers was significantly higher (P<0.001) compared to the signal obtained after MB Control administration (Figure 2 ). In the same mice, binding specificity of MB VEGFR2 to VEGFR2 was further verified by in vivo blocking of the VEGFR2 receptor with anti-VEGFR2 antibody, which significantly (P<0.001) decreased the signal by 87% on average ( Figure 2 ). Overall, these results confirmed in vivo binding specificity of clinical grade MB VEGFR2 to murine VEGFR2 in transgenic mice and demonstrated presence of increased VEGFR2 expression over a broad range of breast cancer tumor sizes.
Molecular ultrasound imaging signal increases as the mouse breast tissue progresses from normal to cancer.
We then assessed the in vivo ultrasound molecular imaging signal in 315 mammary glands randomly scanned at different ages between weeks 4 and 10. Figure 3 summarizes the distribution of the four histological types (normal, hyperplasia, DCIS, invasive cancer) among all mammary glands. At age 4 weeks, many mammary glands already showed histological features of hyperplasia or DCIS; 30% of the mammary glands showed normal mammary tissue at that age. Presence of hyperplasia peaked in week 5 (29% of mammary glands ). DCIS was the predominant histological feature between weeks 4 and 8 with a peak at week 7. Invasive breast cancer was first noted at week 7 and by week 10, 94% of mammary glands showed histological features of invasive breast cancer.
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Author Manuscript Published OnlineFirst on January 17, 2013; DOI: 10.1158/0008-5472.CAN-12-3391 P=0.021). When breast tissue further progressed from hyperplasia to DCIS, mean ultrasound molecular imaging significantly increased to 15.95 ± 1.31 a.u. (P<0.001). Imaging signal further significantly increased (P<0.001) when DCIS progressed to invasive breast cancer (78.1 ± 6.31 a.u.) ( Figure 4A & 4B) . Imaging signal in breast cancer was 47.3-fold higher compared to normal breast tissue, 18.6-fold higher compared to hyperplasia, and 4.9-fold higher compared to DCIS.
VEGFR2 expression increases with breast tissue progression from normal, hyperplasia,
DCIS, to invasive breast cancer.
Following ultrasound imaging, mice were sacrificed and tumors excised for ex vivo analysis. VEGFR2 expression was significantly increased (P<0.001) in hyperplasia, DCIS, and invasive breast cancer compared to normal breast tissue, and was highest on the angiogenic vasculature of invasive breast cancer ( Figure 5 ). Quantitative VEGFR2-based immunofluorescence signal strongly correlated with in vivo VEGFR2-targeted ultrasonic molecular imaging (R 2 =0.84; 95% CI, 0.72, 0.91; P<0.001). In addition to higher VEGFR2 expression levels, MVD significantly (P0.001) increased in hyperplasia, DCIS, and invasive breast cancer compared to normal tissue, suggesting that increased in vivo VEGFR2-targeted imaging signal during breast tissue progression from normal to invasive breast cancer was caused by a combination of higher target expression per vessel and an increase in the overall number of vessels expressing the target VEGFR2. Using a linear regression model, the fitted equation reflecting the association between in vivo ultrasonic imaging signal, QIF, and MVD was: Ultrasound signal = 0.11*MVD +3.55*QIF-0.47. The quantitative value generated by this equation is referred to as the angiogenesis score, and represents a combination of the number of vessels expressing the VEGFR2 and VEGFR2 expression per vessel. The angiogenesis score significantly increased (P0.001) from normal to hyperplasia, DCIS or invasive subtypes of breast cancer in this transgenic mouse model (Supplementary Figure S1) . The adjusted coefficient of correlation was 0.74 (95% CI, 0.51, 0.89; P0.001), suggesting good correlation between in vivo ultrasonic molecular imaging signal and both MVD and VEGFR2 expression levels on the vasculature. Overall, ultrasound allowed the differentiation of benign from malignant diseases with high diagnostic accuracy (AUC of 0.94). Sensitivities, specificities, and positive and negative predictive values to differentiate benign from malignant cases using different imaging signal threshold levels were calculated and are summarized in Supplementary Tables S1 and S2 . At a threshold level of 4.6 a.u., benign and malignant histological entities were predicted to be diagnosed with a sensitivity of 84% (95% CI, 78, 88) and a specificity of 89% (95% CI, 81, 94) ( Supplementary   Table S1 ).
Using the threshold level of 4.6 a.u., two readers analyzed an additional 63 mammary glands in a prospective screening setting (20 glands each with normal, DCIS, and invasive cancer; 3 hyperplastic glands). In this trial, malignant lesions were differentiated from benign lesions with a sensitivity of 100% (95% CI, 91, 100) and a specificity of 87% (95% CI, 66, 97) for both readers, respectively (Table 1a ). Both readers overcalled three benign findings (one normal mammary gland and two glands with hyperplasia) as malignant (Table 1b ). Discrepancies between both readers were observed in only 2/63 cases ( 
DISCUSSION
Our study showed that VEGFR2-targeted ultrasound imaging signal increases when mammary glands progress from normal tissue to hyperplasia, DCIS, and invasive breast cancer in a transgenic mouse model. At an ultrasound molecular imaging signal threshold level of 4.6 a.u., DCIS and invasive breast cancer can be differentiated from normal and hyperplastic mammary glands with high sensitivity and specificity. Our results suggest that VEGFR2-targeted contrast MB can increase the diagnostic accuracy of ultrasound in earlier detection of both breast cancer and its precursor lesion DCIS. Ultrasound (7, 34, 35) and other imaging technologies such as MRI (36, 37) and PET (38) are currently being evaluated as adjunct screening modalities in patients with mammographically dense breasts since screening mammograms can miss breast cancer in more than 50% of patients with dense breast tissue (4, 5) . In fact, in several states in the United States dense breast laws have recently been passed that mandate radiologists to specifically inform patients about the presence of dense breast tissue on mammograms, acknowledging the limited sensitivity of mammography in detecting breast cancer in these patients. However, the diagnostic accuracy of current ultrasound screening techniques in breast cancer detection is low (39) .
We explored whether the diagnostic accuracy of ultrasound in earlier breast cancer detection could be improved by molecular imaging of tumor angiogenesis in a mouse model. To simulate the apparent progression of ductal breast adenocarcinoma from normal to hyperplasia, DCIS, and invasive breast cancer as observed in patients, and to quantify the ultrasound molecular imaging signal associated with these four histological stages, we used a transgenic mouse model that recapitulates this progression in murine mammary glands. We found that the angiogenic switch, the stage at which angiogenesis occurs in tumor progression, can already be observed to some Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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We then confirmed our hypothesis that in vivo ultrasound molecular imaging signal using a contrast agent targeted at tumor angiogenesis significantly increases during breast cancer development by correlating in vivo ultrasonic molecular imaging findings with ex vivo histopathological findings in 315 mammary glands. Quantitative immunofluorescence showed that both the number of angiogenic vessels and the ex vivo expression levels of VEGFR2 per vessel strongly correlated with in vivo ultrasound molecular imaging signal across the four different breast histologies. Collectively, these findings indicate that tumor angiogenesis including overexpression of angiogenic markers such as VEGFR2 may play a significant role in breast cancer progression in this mouse model, and that imaging and quantification of tumor angiogenesis using VEGFR2-targeted ultrasound contrast agents could be leveraged to aid in the earlier detection of clinically relevant findings such as DCIS and invasive breast cancer by defining imaging signal threshold levels.
This was further tested in a blinded prospective screening trial by using newly defined ultrasound molecular imaging signal threshold levels. To simulate a clinical scenario with "patients" at risk to develop breast cancer, transgenic and wild-type mice were randomly selected at various ages and prospectively screened with ultrasound molecular imaging, followed by direct ex vivo correlation with the in vivo imaging results. Our results in 63 prospectively analyzed mammary glands showed that clinically actionable findings such as DCIS and invasive breast cancer can be detected with a sensitivity of up to 100%, which was higher than the predicted value of 84% obtained from the previous part of our study. An explanation of this high sensitivity is the observation that all 20 DCIS and 20 invasive breast cancer cases included in this prospective screening trial happened to show high levels of VEGFR2 and MVD and thus, the ultrasound molecular imaging signal was measured above the pre-selected threshold level value of 4.6 a.u..
Both readers highly agreed between each other in differentiating malignant from benign disease and the false positive rate was low, resulting in a PPV as high as 93%. This suggests that ultasound molecular imaging has the potential not only to increase detection rates of DCIS and on July 20, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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We acknowledge several limitations of our study. First, we acknowledge that the fast progression of mammary tissue over several weeks in the transgenic mouse model may not reflect the usually slow development of breast cancer in patients. This rapid transition may have artificially overstimulated angiogenesis and subsequently VEGFR2 expression in DCIS and invasive cancer in our study. Second, this mouse model does not develop other benign lesions beyond hyperplasia and additional studies are needed to assess whether ultrasound allows differentiation of those lesions from DCIS and breast cancer based on the magnitude of the molecular imaging signal.
Third, the prevalence of DCIS and invasive breast cancer in our mouse screening trial was higher than that in a clinical screening population; this may have overestimated positive and negative predictive values for ultrasound molecular imaging. Fourth, the injected microbubble dose was used according to previous experience in ultrasound molecular imaging of mice (26, 32, 41) . The contrast agent dosing when scaling to future first in man clinical trials need to be assessed and may differ compared to the dosing used in mice. Finally, we acknowledge that with the current imaging equipment available we scanned only a two-dimensional imaging plane from the center of the breast lesions. Ongoing research explores volumetric ultrasound molecular imaging approaches to assess the molecular signature from the entire three-dimensional extent of the target tissues.
In conclusion, our results suggest that ultrasound molecular imaging using a novel clinical-grade VEGFR2-targeted ultrasound contrast agent allows highly accurate and reliable detection of DCIS and breast cancer in a screening trial of transgenic mice. This study lays the foundation for further development of this promising imaging approach for earlier breast cancer detection and paves the way for translational clinical trials in the future.
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